Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1391 ARTÍCULOS , VIENDO DEL 586 AL 600

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease

Kalra J, Khan A.

Eur J Pharmacol. 2015 Oct 5;764:571-581. doi: 10.1016/j.ejphar.2015.07.043. Epub 2015 Jul 21.

Drawing in Alzheimer-type dementia

Fichera M, Bernasconi MP, Martinelli V, Comi G, Volonté MA.

Neurology. 2015 Jul 28;85(4):386-7. doi: 10.1212/WNL.0000000000001789.

Cognitively Impaired Sexually Abused Women: The Most Vulnerable of All?

Tullmann D.

Issues Ment Health Nurs. 2015 Jun;36(6):474-7. doi: 10.3109/01612840.2014.994690.

[The scientific discourse about dementia in Germany-first results of the exemplary exercise of an integrative methodological approach]

Panke-Kochinke B, Krause G, Klimann O.

Pflege. 2015 Aug;28(4):219-32. doi: 10.1024/1012-5302/a000435.

Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease

Wang F, Gordon BA, Ryman DC, Ma S, Xiong C, Hassenstab J, Goate A, Fagan AM, Cairns NJ, Marcus DS, McDade E, Ringman JM, Graff-Radford NR, Ghetti B, Farlow MR, Sperling R, Salloway S, Schofield PR, Masters CL, Martins RN, Rossor MN, Jucker M, Danek A, Förster S, Lane CA, Morris JC, Benzinger TL, Bateman RJ; Dominantly Inherited Alzheimer Network.

Neurology. 2015 Sep 1;85(9):790-8. doi: 10.1212/WNL.0000000000001903. Epub 2015 Aug 5.

Is dominantly inherited Alzheimer disease a clone of sporadic Alzheimer disease?

Knopman DS.

Neurology. 2015 Sep 1;85(9):750-1. doi: 10.1212/WNL.0000000000001897. Epub 2015 Aug 5.

What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?

Becker RE, Seeman MV, Greig NH, Lahiri DK.

Lancet Psychiatry. 2015 Aug;2(8):756-764. doi: 10.1016/S2215-0366(15)00214-X.

Current thinking on the mechanistic basis of Alzheimer's and implications for drug development

Ising C, Stanley M, Holtzman DM.

Clin Pharmacol Ther. 2015 Nov;98(5):469-71. doi: 10.1002/cpt.200. Epub 2015 Sep 10.

Optical Coherence Tomography in Alzheimer's Disease: A Meta-Analysis

Coppola G, Di Renzo A, Ziccardi L, Martelli F, Fadda A, Manni G, Barboni P, Pierelli F, Sadun AA, Parisi V.

PLoS One. 2015 Aug 7;10(8):e0134750. doi: 10.1371/journal.pone.0134750. eCollection 2015.

Vibrational spectroscopic analysis of peripheral blood plasma of patients with Alzheimer's disease

Carmona P, Molina M, López-Tobar E, Toledano A.

Anal Bioanal Chem. 2015 Oct;407(25):7747-56. doi: 10.1007/s00216-015-8940-7. Epub 2015 Aug 9.

Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir

Trembath L, Newell M, Devous MD Sr.

J Nucl Med Technol. 2015 Sep;43(3):175-84. doi: 10.2967/jnmt.115.156679. Epub 2015 Aug 13.

Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease

Leurent C, Ehlers MD.

Clin Pharmacol Ther. 2015 Nov;98(5):475-6. doi: 10.1002/cpt.212. Epub 2015 Sep 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias